SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to one new employee to purchase an aggregate of 2,500 shares of the Company’s common stock, effective as of November 1, 2024. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company’s 2022 Inducement Plan, with a grant date of November 1, 2024, as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Robex Reports Q3 2024 Results - December 2, 2024
- Asia Pacific Wire & Cable Corporation Limited Reports Third Quarter 2024 Financial Results - December 2, 2024
- Alico, Inc. Announces Financial Results for the Fourth Quarter and Fiscal Year Ended September 30, 2024 - December 2, 2024
